Mike Dudley
@MikeMndudley
Followers
397
Following
3K
Media
24
Statuses
428
President, CEO and co-Founder of antibiotics innovator Qpex Biopharma in San Diego, now a Shionogi Group company. Rust never sleeps.
San Diego
Joined October 2014
We are delighted to have you join the Qpex Team!
Welcome Lynn Connolly, MD, PhD as Chief Medical Officer. With more than 12 years of experience in developing infectious disease treatments, she will lead our clinical development programs and help drive innovation in our expanding drug discovery programs.
1
0
7
It’s time for a new game plan…
Faster, higher, stronger - together! 🥇 Join us to hear SIDP founding member Dr. @MikeMndudley deliver the Keynote Address at the Annual meeting! Free member registration by 9/30 (fee for onsite reg) or 10/14 (virtual attendance). https://t.co/uxuamq0Wqj
#SIDP2024 #IDWeek2024
0
2
14
“This is a landmark opportunity to build upon the excellent track record of our organizations in discovering innovative antimicrobial drugs and bringing them to patients” @SIDPharm @CARB_X @AMRActionFund @ABsteward @IDSAInfo @pewhealth @gardp_amr
#BIO2024 Announcement: We’re expanding research operations through our first discovery laboratory in the U.S. This new facility for @Qpexbio, a Shionogi Group Company, will increase capabilities in infectious disease. Learn more: https://t.co/l0SpZNXVeB
1
1
11
Over 40 yrs ago, Dr Steve Zinner took me under his wing and introduced me to the hollow fiber PK-PD system he developed- now foundational in antibiotic R&D. And he is still presenting work @ESCMID ! Long may you run my dear friend.
1
0
28
We discuss doing a better job communicating on #AMR. Messaging "it's a really big problem” has failed to reform pricing to feed investment for new drugs. Confuses policymakers.Find out why AMR is more like “rare” dx.@AWG_News @SIDPharm @CARB_X @gardp_amr @IDSAInfo @pewhealth
🆕 #Breakpoints Episode: Join @hboucher3, Ramy Elshaboury, @MikeMNDudley & @MeganKlatt3 to discuss barriers to abx drug development, incentives & legislation to promote market growth, & what we can do to ensure the abx pipeline doesn’t run dry. 🎧 https://t.co/ez0n3ae0fR
1
1
7
Getting new antibiotics is fundamentally a revenue & insurance problem. Restore the investment/innovation/revenue cycle with new tools for quantifying value. Same policy talking points aren't working. Step-up the game. @gardp_amr @AWG_News @AMRActionFund @pewhealth @SIDPharm
🆕 #Breakpoints Episode: Join @hboucher3, Ramy Elshaboury, @MikeMNDudley & @MeganKlatt3 to discuss barriers to abx drug development, incentives & legislation to promote market growth, & what we can do to ensure the abx pipeline doesn’t run dry. 🎧 https://t.co/ez0n3ae0fR
0
2
10
Can anyone explain to me why they have these talks in noisy traffic areas with uncomfortable/ limited seating where larger halls just around the corner sit empty? @IDWeekmtg please—let’s not do this anymore! @idpharmd @SIDPharm
0
0
6
Beta-lactamase inhibitors have been an important strategy for combatting #AMR. Want to finally see comparative head-to-head data on investigational & marketed beta-lactamase inhibitors? We publish results here…
journals.asm.org
Restoration of β-lactam (BL) antibiotic potency with β-lactamase inhibitors (BLIs) is a proven strategy that was introduced with marketed products in the mid-80s and continues to be an important...
0
8
18
Class act or what!? @jpogue1 @ClancyNeil
The Pittsburgh Penguins have been using players to hand deliver season tickets since 2007, which has to be one of the coolest traditions in sports. Imagine Sidney Crosby walking up to your house! https://t.co/fOfEnTEHZL
2
0
2
#AMR due to NDM beta-lactamase continues to amaze in its evolution, including NDM-9 & resistance to some beta-lactamase inhibitors. We describe here: https://t.co/VrJ2ApHFFI
0
0
0
It just doesn’t get any better than this! Thanks to @julie_justo and @SIDPharm for a great discussion.
Warning...the nerd factor in the upcoming @SIDPharm #Breakpoints podcast 🎙️ episode on BLI PK-PD with our good friends, @MikeMndudley & Paul Ambrose, is pretty epic! Buckle up for a lot of modeling & med chem. It makes all 3 of us happy.🤓 #IDTwitter #TwitteRx
0
1
16
Indeed- enjoyed our discussion David!
Thank you David… we agree! https://t.co/UrazbqjYIF
@SIDPharm @AWG_News @IDSAInfo @CARB_X @koutterson @pewresearch @gardp_amr
0
0
2
Both Shionogi and @Qpex share a deep commitment to innovation in the development of products for infectious diseases. @AWG_News @CARB_X @SIDPharm @IDSAInfo @AMRActionFund @koutterson @BARDA @AMRAlliance @AllianceBEAM @TimothyJinks1 @gardp_amr @PearlF
“Qpex is thrilled to become part of Shionogi, a world-class organization with an established legacy and commitment to innovation in the development of products for the treatment of infectious diseases,” said Michael N. Dudley, PharmD, CEO of Qpex.
2
3
28
What's going on with the NDM-9 metallo beta-lactamase? Are there differences in inhibition by new boronate B-inhibitors? Come hear an Emerging Science presentation by Qpex's Olga Lomovskaya on Sat 6/17 @ 2:30pm in Lounge & Learn Area 2. It's Rapid Fire-don't be late! #ASMicrobe
1
0
2
1
0
0
This is particularly egregious when it’s antibiotic therapy in fragile patients. @SIDPharm @AWG_News @IDSAInfo @CARB_X @AMRActionFund @Wellcome_AMR @lisamurkowski @RepRaulRuizMD
washingtonpost.com
Insurers often require prior authorization for new drugs, leading to treatment delays. New laws may force plans to make exceptions and speed up the process.
0
1
5
Also, xeruborbactam (formerly QPX7728) Phase 1 PK for IV and oral dosing in Posters #216 & 218, and PK-PD results on #614-5. @SIDPharm @IDWeek2022 #IDWeek2022 @IDSAInfo @AWG_News
Want to see @IDWeek2022 of xeruborbactam head-to-head testing vs invest IV & oral beta-lactam/betaL-ase inhibs or activity vs DTR #AMR vs pathogens. TODAY: See posters 1692-3 by Olga Lomovskaya @mcastanheirajmi, & # 1736-7 by @IDPittStop Hong Nguyen, @ClancyNeil @ryankshields
0
0
2
Going to be a busy week. Congrats and thanks to the Qpex Team and our collaborators. @ClancyNeil @ryankshields @gardp_amr @IDSAInfo #IDWeek2022 @BARDA @SIDPharm #AMR #IDTwitter @ABsteward @A_baumannii #TwitteRx
10 presentations at #IDWEEK202 on Qpex’s investigational products that the recent WHO pipeline analysis identified as addressing #AMR pathogens where there is a critical need for new drugs. @AWG_News @SIDPharm @IDWeek2022 @CARB_X
0
2
6